复方苦参注射液治疗非小细胞肺癌的快速卫生技术评估  

Rapid Health Technology Assessment of Compound Kushen Injection in the Treatment of Non-Small Cell Lung Cancer

作　　者：张碧华[1] 陈福安[1] 黄飞[2] 杨莉萍[1] ZHANG Bihua;CHEN Fuan;HUANG Fei;YANG Liping(Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China;Dept.of Traditional Chinese Medicine,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730 [2]北京医院中医科,国家老年医学中心,中国医学科学院老年医学研究院,北京100730

出　　处：《中国医院用药评价与分析》2023年第5期592-595,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：北京市中医药科技发展资金项目(No.JJ-2020-32)。

摘　　要：目的:利用循证证据,评估复方苦参注射液治疗非小细胞肺癌(NSCLC)的有效性、经济性和安全性,为该药的临床使用提供相关循证依据。方法:系统检索中国生物医学文献数据库、中国知网、万方数据库、国际卫生技术评估协会、国际卫生技术评估网络、PubMed、the Cochrane Library和Embase等网站(检索时限为建库至2022年9月30日),汇总复方苦参注射液治疗NSCLC的卫生技术评估(HTA)报告、Meta分析/系统评价、药物经济学研究等资料,并对文献及其方法学进行质量评价和分析。结果:共纳入13篇文献,其中Meta分析/系统评价11篇,药物经济学研究2篇,HTA报告未检索到。结果显示,复方苦参注射液治疗NSCLC,在提高总有效率、疾病控制率和1年生存率,改善患者生活质量以及缓解疼痛等方面均有一定的优势。安全性研究结果显示,复方苦参注射液联合放化疗治疗NSCLC能有效减少不良反应,安全性更好。药物经济学评价分别将复方苦参注射液与空白对照、艾迪注射液进行了对比研究,结果表明,复方苦参注射液联合化疗能提高患者的生活质量和延长患者的生存期,且具有一定的成本效用优势;但与艾迪注液相比,其经济性处于劣势。结论:复方苦参注射液治疗NSCLC有助于提高临床疗效,改善评价指标,减少放化疗不良反应。未来有待于进一步开展更规范的临床观察及相关药物经济学研究,补充更高质量的循证证据。OBJECTIVE:To evaluate the efficacy,economical efficiency and safety of compound Kushen injection in the treatment of non-small cell lung cancer(NSCLC),so as to provide evidence for clinical rational drug use.METHODS:CBM,CNKI,Wanfang Data,INAHTA and HTAI databases or organization websites,PubMed,the Cochrane Library and Embase were retrieved to collect health technology assessment(HTA)reports,Meta-analysis/systematic review,and pharmacoeconomic studies of compound Kushen injection in the treatment of NSCLC(search deadline was until Sept.30th,2022).The quality of literature and its methodology were evaluated and analyzed.RESULTS:A total of 13 articles were included.Among them 11 studies were conducted on Meta-analysis/systematic review,2 studies were conducted on pharmacoeconomics,HTA were not obtained.Results showed that compound Kusen injection in the treatment of NSCLC had certain advantages in improving the total effective rate,disease control rate and one-year survival rate,improving the quality of life of patients and relieving pain.Results of safety study showed that compound Kushenshen injection combined with radiotherapy and chemotherapy in the treatment of NSCLC could effectively reduce adverse drug reactions with higher safety.In pharmacoeconomic evaluation,compound Kushen injection was compared with blank control and Aidi injection,results showed that compound Kushen injection combined with chemotherapy could improve the quality of life and prolong the survival time of patients,and had certain cost-utility advantages.However,it was economically inferior compared with Addy injection.CONCLUSIONS:Compound Kushen injection in the treatment of NSCLC can help to improve clinical efficacy and evaluation indicators,reduce the toxic and side effects of radiotherapy and chemotherapy.In the future,more standardized clinical observation and related pharmacoeconomic research need to be further carried out to supplement higher-quality evidence-based evidence.

关 键 词：复方苦参注射液 非小细胞肺癌 卫生经济学 快速卫生技术评估 

分 类 号：R932[医药卫生—生药学]